nodes	percent_of_prediction	percent_of_DWPC	metapath
Paliperidone—CYP3A5—Daunorubicin—hematologic cancer	0.0248	0.0507	CbGbCtD
Paliperidone—CYP2D6—Lomustine—hematologic cancer	0.0242	0.0493	CbGbCtD
Paliperidone—CYP3A5—Thalidomide—hematologic cancer	0.0226	0.0462	CbGbCtD
Paliperidone—CYP3A5—Teniposide—hematologic cancer	0.0216	0.044	CbGbCtD
Paliperidone—CYP2D6—Idarubicin—hematologic cancer	0.0215	0.0439	CbGbCtD
Paliperidone—CYP3A5—Ifosfamide—hematologic cancer	0.0199	0.0406	CbGbCtD
Paliperidone—CYP3A5—Imatinib—hematologic cancer	0.019	0.0388	CbGbCtD
Paliperidone—CYP2D6—Hydroxyurea—hematologic cancer	0.0183	0.0373	CbGbCtD
Paliperidone—CYP3A4—Bexarotene—hematologic cancer	0.0165	0.0337	CbGbCtD
Paliperidone—CYP2D6—Bortezomib—hematologic cancer	0.0159	0.0325	CbGbCtD
Paliperidone—CYP3A4—Busulfan—hematologic cancer	0.0154	0.0313	CbGbCtD
Paliperidone—CYP3A4—Lomustine—hematologic cancer	0.0154	0.0313	CbGbCtD
Paliperidone—CYP3A5—Dasatinib—hematologic cancer	0.0153	0.0312	CbGbCtD
Paliperidone—CYP3A4—Thiotepa—hematologic cancer	0.0137	0.0279	CbGbCtD
Paliperidone—CYP3A5—Irinotecan—hematologic cancer	0.0119	0.0242	CbGbCtD
Paliperidone—CYP2D6—Imatinib—hematologic cancer	0.0117	0.0238	CbGbCtD
Paliperidone—CYP3A4—Methoxsalen—hematologic cancer	0.0107	0.0217	CbGbCtD
Paliperidone—CYP2D6—Nilotinib—hematologic cancer	0.0106	0.0216	CbGbCtD
Paliperidone—CYP2D6—Vinorelbine—hematologic cancer	0.0105	0.0214	CbGbCtD
Paliperidone—CYP3A5—Vincristine—hematologic cancer	0.0104	0.0212	CbGbCtD
Paliperidone—CYP3A4—Bortezomib—hematologic cancer	0.0101	0.0207	CbGbCtD
Paliperidone—CYP3A4—Daunorubicin—hematologic cancer	0.00969	0.0198	CbGbCtD
Paliperidone—CYP3A5—Etoposide—hematologic cancer	0.00952	0.0194	CbGbCtD
Paliperidone—CYP3A4—Cytarabine—hematologic cancer	0.00855	0.0174	CbGbCtD
Paliperidone—CYP3A4—Teniposide—hematologic cancer	0.00842	0.0172	CbGbCtD
Paliperidone—CYP3A5—Dexamethasone—hematologic cancer	0.00783	0.016	CbGbCtD
Paliperidone—CYP3A4—Ifosfamide—hematologic cancer	0.00777	0.0158	CbGbCtD
Paliperidone—CYP3A4—Imatinib—hematologic cancer	0.00742	0.0151	CbGbCtD
Paliperidone—CYP3A4—Ruxolitinib—hematologic cancer	0.00699	0.0143	CbGbCtD
Paliperidone—CYP3A4—Nilotinib—hematologic cancer	0.00674	0.0138	CbGbCtD
Paliperidone—CYP3A4—Vinorelbine—hematologic cancer	0.00669	0.0136	CbGbCtD
Paliperidone—CYP2D6—Vinblastine—hematologic cancer	0.00648	0.0132	CbGbCtD
Paliperidone—CYP3A4—Triamcinolone—hematologic cancer	0.00612	0.0125	CbGbCtD
Paliperidone—CYP3A4—Dasatinib—hematologic cancer	0.00596	0.0122	CbGbCtD
Paliperidone—CYP3A4—Mitoxantrone—hematologic cancer	0.00589	0.012	CbGbCtD
Paliperidone—CYP3A4—Betamethasone—hematologic cancer	0.00525	0.0107	CbGbCtD
Paliperidone—CYP3A4—Prednisolone—hematologic cancer	0.00518	0.0106	CbGbCtD
Paliperidone—CYP3A4—Prednisone—hematologic cancer	0.00489	0.00997	CbGbCtD
Paliperidone—CYP2D6—Dexamethasone—hematologic cancer	0.0048	0.00979	CbGbCtD
Paliperidone—CYP3A4—Irinotecan—hematologic cancer	0.00464	0.00945	CbGbCtD
Paliperidone—CYP3A4—Vinblastine—hematologic cancer	0.00412	0.00841	CbGbCtD
Paliperidone—CYP3A4—Vincristine—hematologic cancer	0.00405	0.00826	CbGbCtD
Paliperidone—CYP2D6—Doxorubicin—hematologic cancer	0.00398	0.00812	CbGbCtD
Paliperidone—CYP3A4—Etoposide—hematologic cancer	0.00371	0.00757	CbGbCtD
Paliperidone—Risperidone—H1F0—hematologic cancer	0.00365	0.906	CrCbGaD
Paliperidone—CYP3A4—Dexamethasone—hematologic cancer	0.00305	0.00623	CbGbCtD
Paliperidone—CYP3A4—Doxorubicin—hematologic cancer	0.00253	0.00516	CbGbCtD
Paliperidone—Risperidone—ABCB1—hematologic cancer	0.000377	0.0937	CrCbGaD
Paliperidone—DRD4—testis—hematologic cancer	0.000158	0.0947	CbGeAlD
Paliperidone—HTR1A—hematopoietic system—hematologic cancer	9.48e-05	0.0568	CbGeAlD
Paliperidone—ADRA1A—hematopoietic system—hematologic cancer	8.74e-05	0.0524	CbGeAlD
Paliperidone—CYP3A5—hematopoietic system—hematologic cancer	6.97e-05	0.0418	CbGeAlD
Paliperidone—HRH1—hematopoietic system—hematologic cancer	6.76e-05	0.0406	CbGeAlD
Paliperidone—ADRA2A—hematopoietic system—hematologic cancer	6.64e-05	0.0398	CbGeAlD
Paliperidone—ADRA1A—blood—hematologic cancer	5.79e-05	0.0347	CbGeAlD
Paliperidone—HTR2A—hematopoietic system—hematologic cancer	5.65e-05	0.0339	CbGeAlD
Paliperidone—ADRA2C—blood—hematologic cancer	5.52e-05	0.0331	CbGeAlD
Paliperidone—CYP3A4—hematopoietic system—hematologic cancer	5.23e-05	0.0314	CbGeAlD
Paliperidone—CYP2D6—hematopoietic system—hematologic cancer	5.15e-05	0.0309	CbGeAlD
Paliperidone—ADRA2A—gonad—hematologic cancer	5.05e-05	0.0303	CbGeAlD
Paliperidone—DRD2—lung—hematologic cancer	4.97e-05	0.0298	CbGeAlD
Paliperidone—ADRA2C—lung—hematologic cancer	4.84e-05	0.029	CbGeAlD
Paliperidone—DRD2—testis—hematologic cancer	4.69e-05	0.0281	CbGeAlD
Paliperidone—CYP3A5—blood—hematologic cancer	4.62e-05	0.0277	CbGeAlD
Paliperidone—ADRA2C—testis—hematologic cancer	4.56e-05	0.0274	CbGeAlD
Paliperidone—ADRA2A—blood—hematologic cancer	4.4e-05	0.0264	CbGeAlD
Paliperidone—HTR2A—gonad—hematologic cancer	4.29e-05	0.0258	CbGeAlD
Paliperidone—CYP3A5—lung—hematologic cancer	4.05e-05	0.0243	CbGeAlD
Paliperidone—HRH1—lung—hematologic cancer	3.93e-05	0.0236	CbGeAlD
Paliperidone—ADRA2A—lung—hematologic cancer	3.86e-05	0.0231	CbGeAlD
Paliperidone—HTR2A—blood—hematologic cancer	3.74e-05	0.0224	CbGeAlD
Paliperidone—HRH1—testis—hematologic cancer	3.71e-05	0.0222	CbGeAlD
Paliperidone—ADRA2A—testis—hematologic cancer	3.64e-05	0.0218	CbGeAlD
Paliperidone—CYP3A4—blood—hematologic cancer	3.46e-05	0.0208	CbGeAlD
Paliperidone—CYP2D6—blood—hematologic cancer	3.41e-05	0.0204	CbGeAlD
Paliperidone—ADRA2C—lymph node—hematologic cancer	3.31e-05	0.0198	CbGeAlD
Paliperidone—HTR2A—lung—hematologic cancer	3.28e-05	0.0197	CbGeAlD
Paliperidone—HTR2A—testis—hematologic cancer	3.1e-05	0.0186	CbGeAlD
Paliperidone—CYP2D6—testis—hematologic cancer	2.82e-05	0.0169	CbGeAlD
Paliperidone—HRH1—lymph node—hematologic cancer	2.69e-05	0.0161	CbGeAlD
Paliperidone—ADRA2A—lymph node—hematologic cancer	2.64e-05	0.0158	CbGeAlD
Paliperidone—Feeling abnormal—Dexamethasone—hematologic cancer	2.4e-05	6.32e-05	CcSEcCtD
Paliperidone—Feeling abnormal—Betamethasone—hematologic cancer	2.4e-05	6.32e-05	CcSEcCtD
Paliperidone—Flushing—Doxorubicin—hematologic cancer	2.39e-05	6.31e-05	CcSEcCtD
Paliperidone—Cardiac disorder—Doxorubicin—hematologic cancer	2.39e-05	6.31e-05	CcSEcCtD
Paliperidone—Flatulence—Epirubicin—hematologic cancer	2.39e-05	6.31e-05	CcSEcCtD
Paliperidone—Tension—Epirubicin—hematologic cancer	2.38e-05	6.28e-05	CcSEcCtD
Paliperidone—Gastrointestinal pain—Dexamethasone—hematologic cancer	2.38e-05	6.27e-05	CcSEcCtD
Paliperidone—Gastrointestinal pain—Betamethasone—hematologic cancer	2.38e-05	6.27e-05	CcSEcCtD
Paliperidone—Dysgeusia—Epirubicin—hematologic cancer	2.38e-05	6.27e-05	CcSEcCtD
Paliperidone—Hypersensitivity—Triamcinolone—hematologic cancer	2.36e-05	6.23e-05	CcSEcCtD
Paliperidone—Nervousness—Epirubicin—hematologic cancer	2.36e-05	6.22e-05	CcSEcCtD
Paliperidone—Back pain—Epirubicin—hematologic cancer	2.35e-05	6.19e-05	CcSEcCtD
Paliperidone—Angiopathy—Doxorubicin—hematologic cancer	2.34e-05	6.17e-05	CcSEcCtD
Paliperidone—Malaise—Methotrexate—hematologic cancer	2.34e-05	6.17e-05	CcSEcCtD
Paliperidone—Dizziness—Etoposide—hematologic cancer	2.34e-05	6.16e-05	CcSEcCtD
Paliperidone—Muscle spasms—Epirubicin—hematologic cancer	2.33e-05	6.15e-05	CcSEcCtD
Paliperidone—Immune system disorder—Doxorubicin—hematologic cancer	2.33e-05	6.14e-05	CcSEcCtD
Paliperidone—Vertigo—Methotrexate—hematologic cancer	2.33e-05	6.14e-05	CcSEcCtD
Paliperidone—Mediastinal disorder—Doxorubicin—hematologic cancer	2.33e-05	6.13e-05	CcSEcCtD
Paliperidone—Leukopenia—Methotrexate—hematologic cancer	2.32e-05	6.12e-05	CcSEcCtD
Paliperidone—Chills—Doxorubicin—hematologic cancer	2.32e-05	6.1e-05	CcSEcCtD
Paliperidone—Urticaria—Betamethasone—hematologic cancer	2.31e-05	6.09e-05	CcSEcCtD
Paliperidone—Urticaria—Dexamethasone—hematologic cancer	2.31e-05	6.09e-05	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Prednisone—hematologic cancer	2.31e-05	6.08e-05	CcSEcCtD
Paliperidone—Dizziness—Prednisolone—hematologic cancer	2.31e-05	6.08e-05	CcSEcCtD
Paliperidone—Asthenia—Triamcinolone—hematologic cancer	2.3e-05	6.06e-05	CcSEcCtD
Paliperidone—Body temperature increased—Betamethasone—hematologic cancer	2.3e-05	6.06e-05	CcSEcCtD
Paliperidone—Abdominal pain—Betamethasone—hematologic cancer	2.3e-05	6.06e-05	CcSEcCtD
Paliperidone—Body temperature increased—Dexamethasone—hematologic cancer	2.3e-05	6.06e-05	CcSEcCtD
Paliperidone—Abdominal pain—Dexamethasone—hematologic cancer	2.3e-05	6.06e-05	CcSEcCtD
Paliperidone—Nausea—Cisplatin—hematologic cancer	2.29e-05	6.04e-05	CcSEcCtD
Paliperidone—Insomnia—Prednisone—hematologic cancer	2.29e-05	6.04e-05	CcSEcCtD
Paliperidone—Vision blurred—Epirubicin—hematologic cancer	2.29e-05	6.03e-05	CcSEcCtD
Paliperidone—Alopecia—Doxorubicin—hematologic cancer	2.28e-05	6.01e-05	CcSEcCtD
Paliperidone—Paraesthesia—Prednisone—hematologic cancer	2.27e-05	6e-05	CcSEcCtD
Paliperidone—Pruritus—Triamcinolone—hematologic cancer	2.27e-05	5.98e-05	CcSEcCtD
Paliperidone—Cough—Methotrexate—hematologic cancer	2.26e-05	5.97e-05	CcSEcCtD
Paliperidone—Mental disorder—Doxorubicin—hematologic cancer	2.26e-05	5.96e-05	CcSEcCtD
Paliperidone—Ill-defined disorder—Epirubicin—hematologic cancer	2.25e-05	5.94e-05	CcSEcCtD
Paliperidone—Convulsion—Methotrexate—hematologic cancer	2.25e-05	5.92e-05	CcSEcCtD
Paliperidone—Vomiting—Etoposide—hematologic cancer	2.25e-05	5.92e-05	CcSEcCtD
Paliperidone—Erythema—Doxorubicin—hematologic cancer	2.25e-05	5.92e-05	CcSEcCtD
Paliperidone—Malnutrition—Doxorubicin—hematologic cancer	2.25e-05	5.92e-05	CcSEcCtD
Paliperidone—Anaemia—Epirubicin—hematologic cancer	2.24e-05	5.91e-05	CcSEcCtD
Paliperidone—Agitation—Epirubicin—hematologic cancer	2.23e-05	5.88e-05	CcSEcCtD
Paliperidone—Dyspepsia—Prednisone—hematologic cancer	2.23e-05	5.88e-05	CcSEcCtD
Paliperidone—Rash—Etoposide—hematologic cancer	2.23e-05	5.87e-05	CcSEcCtD
Paliperidone—Dermatitis—Etoposide—hematologic cancer	2.23e-05	5.87e-05	CcSEcCtD
Paliperidone—Headache—Etoposide—hematologic cancer	2.21e-05	5.84e-05	CcSEcCtD
Paliperidone—Flatulence—Doxorubicin—hematologic cancer	2.21e-05	5.83e-05	CcSEcCtD
Paliperidone—Chest pain—Methotrexate—hematologic cancer	2.21e-05	5.82e-05	CcSEcCtD
Paliperidone—Arthralgia—Methotrexate—hematologic cancer	2.21e-05	5.82e-05	CcSEcCtD
Paliperidone—Myalgia—Methotrexate—hematologic cancer	2.21e-05	5.82e-05	CcSEcCtD
Paliperidone—Tension—Doxorubicin—hematologic cancer	2.2e-05	5.81e-05	CcSEcCtD
Paliperidone—Decreased appetite—Prednisone—hematologic cancer	2.2e-05	5.8e-05	CcSEcCtD
Paliperidone—Dysgeusia—Doxorubicin—hematologic cancer	2.2e-05	5.8e-05	CcSEcCtD
Paliperidone—Rash—Prednisolone—hematologic cancer	2.2e-05	5.79e-05	CcSEcCtD
Paliperidone—Dermatitis—Prednisolone—hematologic cancer	2.2e-05	5.79e-05	CcSEcCtD
Paliperidone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	2.19e-05	5.78e-05	CcSEcCtD
Paliperidone—Malaise—Epirubicin—hematologic cancer	2.19e-05	5.77e-05	CcSEcCtD
Paliperidone—Fatigue—Prednisone—hematologic cancer	2.18e-05	5.76e-05	CcSEcCtD
Paliperidone—Headache—Prednisolone—hematologic cancer	2.18e-05	5.76e-05	CcSEcCtD
Paliperidone—Discomfort—Methotrexate—hematologic cancer	2.18e-05	5.75e-05	CcSEcCtD
Paliperidone—Nervousness—Doxorubicin—hematologic cancer	2.18e-05	5.75e-05	CcSEcCtD
Paliperidone—Vertigo—Epirubicin—hematologic cancer	2.18e-05	5.75e-05	CcSEcCtD
Paliperidone—Syncope—Epirubicin—hematologic cancer	2.18e-05	5.74e-05	CcSEcCtD
Paliperidone—Leukopenia—Epirubicin—hematologic cancer	2.17e-05	5.73e-05	CcSEcCtD
Paliperidone—Back pain—Doxorubicin—hematologic cancer	2.17e-05	5.73e-05	CcSEcCtD
Paliperidone—Constipation—Prednisone—hematologic cancer	2.17e-05	5.71e-05	CcSEcCtD
Paliperidone—Muscle spasms—Doxorubicin—hematologic cancer	2.16e-05	5.69e-05	CcSEcCtD
Paliperidone—Palpitations—Epirubicin—hematologic cancer	2.15e-05	5.65e-05	CcSEcCtD
Paliperidone—Confusional state—Methotrexate—hematologic cancer	2.13e-05	5.63e-05	CcSEcCtD
Paliperidone—Loss of consciousness—Epirubicin—hematologic cancer	2.13e-05	5.62e-05	CcSEcCtD
Paliperidone—Dizziness—Triamcinolone—hematologic cancer	2.12e-05	5.59e-05	CcSEcCtD
Paliperidone—Cough—Epirubicin—hematologic cancer	2.12e-05	5.58e-05	CcSEcCtD
Paliperidone—Anaphylactic shock—Methotrexate—hematologic cancer	2.12e-05	5.58e-05	CcSEcCtD
Paliperidone—Vision blurred—Doxorubicin—hematologic cancer	2.12e-05	5.58e-05	CcSEcCtD
Paliperidone—Convulsion—Epirubicin—hematologic cancer	2.1e-05	5.54e-05	CcSEcCtD
Paliperidone—Infection—Methotrexate—hematologic cancer	2.1e-05	5.54e-05	CcSEcCtD
Paliperidone—Nausea—Etoposide—hematologic cancer	2.1e-05	5.53e-05	CcSEcCtD
Paliperidone—Hypertension—Epirubicin—hematologic cancer	2.1e-05	5.52e-05	CcSEcCtD
Paliperidone—Feeling abnormal—Prednisone—hematologic cancer	2.09e-05	5.5e-05	CcSEcCtD
Paliperidone—Asthenia—Dexamethasone—hematologic cancer	2.09e-05	5.5e-05	CcSEcCtD
Paliperidone—Asthenia—Betamethasone—hematologic cancer	2.09e-05	5.5e-05	CcSEcCtD
Paliperidone—Ill-defined disorder—Doxorubicin—hematologic cancer	2.08e-05	5.49e-05	CcSEcCtD
Paliperidone—Nervous system disorder—Methotrexate—hematologic cancer	2.08e-05	5.47e-05	CcSEcCtD
Paliperidone—Anaemia—Doxorubicin—hematologic cancer	2.08e-05	5.47e-05	CcSEcCtD
Paliperidone—Thrombocytopenia—Methotrexate—hematologic cancer	2.07e-05	5.46e-05	CcSEcCtD
Paliperidone—Gastrointestinal pain—Prednisone—hematologic cancer	2.07e-05	5.46e-05	CcSEcCtD
Paliperidone—Nausea—Prednisolone—hematologic cancer	2.07e-05	5.46e-05	CcSEcCtD
Paliperidone—Chest pain—Epirubicin—hematologic cancer	2.07e-05	5.45e-05	CcSEcCtD
Paliperidone—Arthralgia—Epirubicin—hematologic cancer	2.07e-05	5.45e-05	CcSEcCtD
Paliperidone—Myalgia—Epirubicin—hematologic cancer	2.07e-05	5.45e-05	CcSEcCtD
Paliperidone—Agitation—Doxorubicin—hematologic cancer	2.06e-05	5.44e-05	CcSEcCtD
Paliperidone—Anxiety—Epirubicin—hematologic cancer	2.06e-05	5.43e-05	CcSEcCtD
Paliperidone—Pruritus—Dexamethasone—hematologic cancer	2.06e-05	5.42e-05	CcSEcCtD
Paliperidone—Pruritus—Betamethasone—hematologic cancer	2.06e-05	5.42e-05	CcSEcCtD
Paliperidone—Skin disorder—Methotrexate—hematologic cancer	2.06e-05	5.42e-05	CcSEcCtD
Paliperidone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	2.05e-05	5.41e-05	CcSEcCtD
Paliperidone—Discomfort—Epirubicin—hematologic cancer	2.04e-05	5.38e-05	CcSEcCtD
Paliperidone—Vomiting—Triamcinolone—hematologic cancer	2.04e-05	5.37e-05	CcSEcCtD
Paliperidone—Malaise—Doxorubicin—hematologic cancer	2.03e-05	5.34e-05	CcSEcCtD
Paliperidone—Rash—Triamcinolone—hematologic cancer	2.02e-05	5.33e-05	CcSEcCtD
Paliperidone—Dry mouth—Epirubicin—hematologic cancer	2.02e-05	5.33e-05	CcSEcCtD
Paliperidone—Dermatitis—Triamcinolone—hematologic cancer	2.02e-05	5.32e-05	CcSEcCtD
Paliperidone—Vertigo—Doxorubicin—hematologic cancer	2.02e-05	5.32e-05	CcSEcCtD
Paliperidone—Anorexia—Methotrexate—hematologic cancer	2.02e-05	5.32e-05	CcSEcCtD
Paliperidone—Syncope—Doxorubicin—hematologic cancer	2.01e-05	5.31e-05	CcSEcCtD
Paliperidone—Urticaria—Prednisone—hematologic cancer	2.01e-05	5.3e-05	CcSEcCtD
Paliperidone—Leukopenia—Doxorubicin—hematologic cancer	2.01e-05	5.3e-05	CcSEcCtD
Paliperidone—Headache—Triamcinolone—hematologic cancer	2.01e-05	5.29e-05	CcSEcCtD
Paliperidone—Body temperature increased—Prednisone—hematologic cancer	2e-05	5.28e-05	CcSEcCtD
Paliperidone—Abdominal pain—Prednisone—hematologic cancer	2e-05	5.28e-05	CcSEcCtD
Paliperidone—Confusional state—Epirubicin—hematologic cancer	2e-05	5.27e-05	CcSEcCtD
Paliperidone—Diarrhoea—Dexamethasone—hematologic cancer	1.99e-05	5.25e-05	CcSEcCtD
Paliperidone—Diarrhoea—Betamethasone—hematologic cancer	1.99e-05	5.25e-05	CcSEcCtD
Paliperidone—Palpitations—Doxorubicin—hematologic cancer	1.98e-05	5.23e-05	CcSEcCtD
Paliperidone—Oedema—Epirubicin—hematologic cancer	1.98e-05	5.22e-05	CcSEcCtD
Paliperidone—Anaphylactic shock—Epirubicin—hematologic cancer	1.98e-05	5.22e-05	CcSEcCtD
Paliperidone—Hypotension—Methotrexate—hematologic cancer	1.98e-05	5.21e-05	CcSEcCtD
Paliperidone—Loss of consciousness—Doxorubicin—hematologic cancer	1.97e-05	5.2e-05	CcSEcCtD
Paliperidone—Infection—Epirubicin—hematologic cancer	1.97e-05	5.19e-05	CcSEcCtD
Paliperidone—Cough—Doxorubicin—hematologic cancer	1.96e-05	5.17e-05	CcSEcCtD
Paliperidone—Shock—Epirubicin—hematologic cancer	1.95e-05	5.14e-05	CcSEcCtD
Paliperidone—Convulsion—Doxorubicin—hematologic cancer	1.95e-05	5.13e-05	CcSEcCtD
Paliperidone—Nervous system disorder—Epirubicin—hematologic cancer	1.94e-05	5.12e-05	CcSEcCtD
Paliperidone—Thrombocytopenia—Epirubicin—hematologic cancer	1.94e-05	5.11e-05	CcSEcCtD
Paliperidone—Hypertension—Doxorubicin—hematologic cancer	1.94e-05	5.11e-05	CcSEcCtD
Paliperidone—Tachycardia—Epirubicin—hematologic cancer	1.93e-05	5.1e-05	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Methotrexate—hematologic cancer	1.93e-05	5.08e-05	CcSEcCtD
Paliperidone—Skin disorder—Epirubicin—hematologic cancer	1.92e-05	5.07e-05	CcSEcCtD
Paliperidone—Dizziness—Dexamethasone—hematologic cancer	1.92e-05	5.07e-05	CcSEcCtD
Paliperidone—Dizziness—Betamethasone—hematologic cancer	1.92e-05	5.07e-05	CcSEcCtD
Paliperidone—Insomnia—Methotrexate—hematologic cancer	1.91e-05	5.05e-05	CcSEcCtD
Paliperidone—Chest pain—Doxorubicin—hematologic cancer	1.91e-05	5.04e-05	CcSEcCtD
Paliperidone—Arthralgia—Doxorubicin—hematologic cancer	1.91e-05	5.04e-05	CcSEcCtD
Paliperidone—Myalgia—Doxorubicin—hematologic cancer	1.91e-05	5.04e-05	CcSEcCtD
Paliperidone—Anxiety—Doxorubicin—hematologic cancer	1.91e-05	5.02e-05	CcSEcCtD
Paliperidone—Nausea—Triamcinolone—hematologic cancer	1.9e-05	5.02e-05	CcSEcCtD
Paliperidone—Paraesthesia—Methotrexate—hematologic cancer	1.9e-05	5.01e-05	CcSEcCtD
Paliperidone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	1.9e-05	5.01e-05	CcSEcCtD
Paliperidone—Discomfort—Doxorubicin—hematologic cancer	1.89e-05	4.98e-05	CcSEcCtD
Paliperidone—Anorexia—Epirubicin—hematologic cancer	1.89e-05	4.98e-05	CcSEcCtD
Paliperidone—Dyspnoea—Methotrexate—hematologic cancer	1.89e-05	4.98e-05	CcSEcCtD
Paliperidone—Somnolence—Methotrexate—hematologic cancer	1.88e-05	4.96e-05	CcSEcCtD
Paliperidone—Dry mouth—Doxorubicin—hematologic cancer	1.87e-05	4.93e-05	CcSEcCtD
Paliperidone—Hypersensitivity—Prednisone—hematologic cancer	1.87e-05	4.92e-05	CcSEcCtD
Paliperidone—Dyspepsia—Methotrexate—hematologic cancer	1.86e-05	4.91e-05	CcSEcCtD
Paliperidone—Hypotension—Epirubicin—hematologic cancer	1.85e-05	4.88e-05	CcSEcCtD
Paliperidone—Vomiting—Dexamethasone—hematologic cancer	1.85e-05	4.88e-05	CcSEcCtD
Paliperidone—Vomiting—Betamethasone—hematologic cancer	1.85e-05	4.88e-05	CcSEcCtD
Paliperidone—Confusional state—Doxorubicin—hematologic cancer	1.85e-05	4.87e-05	CcSEcCtD
Paliperidone—Decreased appetite—Methotrexate—hematologic cancer	1.84e-05	4.85e-05	CcSEcCtD
Paliperidone—Rash—Betamethasone—hematologic cancer	1.83e-05	4.83e-05	CcSEcCtD
Paliperidone—Rash—Dexamethasone—hematologic cancer	1.83e-05	4.83e-05	CcSEcCtD
Paliperidone—Oedema—Doxorubicin—hematologic cancer	1.83e-05	4.83e-05	CcSEcCtD
Paliperidone—Anaphylactic shock—Doxorubicin—hematologic cancer	1.83e-05	4.83e-05	CcSEcCtD
Paliperidone—Dermatitis—Betamethasone—hematologic cancer	1.83e-05	4.83e-05	CcSEcCtD
Paliperidone—Dermatitis—Dexamethasone—hematologic cancer	1.83e-05	4.83e-05	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Methotrexate—hematologic cancer	1.83e-05	4.82e-05	CcSEcCtD
Paliperidone—Fatigue—Methotrexate—hematologic cancer	1.83e-05	4.81e-05	CcSEcCtD
Paliperidone—Headache—Betamethasone—hematologic cancer	1.82e-05	4.8e-05	CcSEcCtD
Paliperidone—Headache—Dexamethasone—hematologic cancer	1.82e-05	4.8e-05	CcSEcCtD
Paliperidone—Infection—Doxorubicin—hematologic cancer	1.82e-05	4.8e-05	CcSEcCtD
Paliperidone—Asthenia—Prednisone—hematologic cancer	1.82e-05	4.79e-05	CcSEcCtD
Paliperidone—Pain—Methotrexate—hematologic cancer	1.81e-05	4.77e-05	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Epirubicin—hematologic cancer	1.81e-05	4.76e-05	CcSEcCtD
Paliperidone—Shock—Doxorubicin—hematologic cancer	1.8e-05	4.75e-05	CcSEcCtD
Paliperidone—Nervous system disorder—Doxorubicin—hematologic cancer	1.8e-05	4.74e-05	CcSEcCtD
Paliperidone—Thrombocytopenia—Doxorubicin—hematologic cancer	1.79e-05	4.73e-05	CcSEcCtD
Paliperidone—Pruritus—Prednisone—hematologic cancer	1.79e-05	4.72e-05	CcSEcCtD
Paliperidone—Insomnia—Epirubicin—hematologic cancer	1.79e-05	4.72e-05	CcSEcCtD
Paliperidone—Tachycardia—Doxorubicin—hematologic cancer	1.79e-05	4.72e-05	CcSEcCtD
Paliperidone—Skin disorder—Doxorubicin—hematologic cancer	1.78e-05	4.69e-05	CcSEcCtD
Paliperidone—Paraesthesia—Epirubicin—hematologic cancer	1.78e-05	4.69e-05	CcSEcCtD
Paliperidone—Dyspnoea—Epirubicin—hematologic cancer	1.77e-05	4.66e-05	CcSEcCtD
Paliperidone—Somnolence—Epirubicin—hematologic cancer	1.76e-05	4.64e-05	CcSEcCtD
Paliperidone—Anorexia—Doxorubicin—hematologic cancer	1.75e-05	4.61e-05	CcSEcCtD
Paliperidone—Feeling abnormal—Methotrexate—hematologic cancer	1.74e-05	4.6e-05	CcSEcCtD
Paliperidone—Dyspepsia—Epirubicin—hematologic cancer	1.74e-05	4.6e-05	CcSEcCtD
Paliperidone—Diarrhoea—Prednisone—hematologic cancer	1.73e-05	4.57e-05	CcSEcCtD
Paliperidone—Gastrointestinal pain—Methotrexate—hematologic cancer	1.73e-05	4.56e-05	CcSEcCtD
Paliperidone—Nausea—Dexamethasone—hematologic cancer	1.73e-05	4.55e-05	CcSEcCtD
Paliperidone—Nausea—Betamethasone—hematologic cancer	1.73e-05	4.55e-05	CcSEcCtD
Paliperidone—Decreased appetite—Epirubicin—hematologic cancer	1.72e-05	4.54e-05	CcSEcCtD
Paliperidone—Hypotension—Doxorubicin—hematologic cancer	1.71e-05	4.52e-05	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Epirubicin—hematologic cancer	1.71e-05	4.51e-05	CcSEcCtD
Paliperidone—Fatigue—Epirubicin—hematologic cancer	1.71e-05	4.5e-05	CcSEcCtD
Paliperidone—Pain—Epirubicin—hematologic cancer	1.69e-05	4.47e-05	CcSEcCtD
Paliperidone—Constipation—Epirubicin—hematologic cancer	1.69e-05	4.47e-05	CcSEcCtD
Paliperidone—Urticaria—Methotrexate—hematologic cancer	1.68e-05	4.43e-05	CcSEcCtD
Paliperidone—Dizziness—Prednisone—hematologic cancer	1.68e-05	4.42e-05	CcSEcCtD
Paliperidone—Abdominal pain—Methotrexate—hematologic cancer	1.67e-05	4.41e-05	CcSEcCtD
Paliperidone—Body temperature increased—Methotrexate—hematologic cancer	1.67e-05	4.41e-05	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	1.67e-05	4.4e-05	CcSEcCtD
Paliperidone—Insomnia—Doxorubicin—hematologic cancer	1.66e-05	4.37e-05	CcSEcCtD
Paliperidone—Paraesthesia—Doxorubicin—hematologic cancer	1.65e-05	4.34e-05	CcSEcCtD
Paliperidone—Dyspnoea—Doxorubicin—hematologic cancer	1.63e-05	4.31e-05	CcSEcCtD
Paliperidone—Feeling abnormal—Epirubicin—hematologic cancer	1.63e-05	4.3e-05	CcSEcCtD
Paliperidone—Somnolence—Doxorubicin—hematologic cancer	1.63e-05	4.3e-05	CcSEcCtD
Paliperidone—Gastrointestinal pain—Epirubicin—hematologic cancer	1.62e-05	4.27e-05	CcSEcCtD
Paliperidone—Dyspepsia—Doxorubicin—hematologic cancer	1.61e-05	4.25e-05	CcSEcCtD
Paliperidone—Vomiting—Prednisone—hematologic cancer	1.61e-05	4.25e-05	CcSEcCtD
Paliperidone—Rash—Prednisone—hematologic cancer	1.6e-05	4.21e-05	CcSEcCtD
Paliperidone—Dermatitis—Prednisone—hematologic cancer	1.6e-05	4.21e-05	CcSEcCtD
Paliperidone—Decreased appetite—Doxorubicin—hematologic cancer	1.59e-05	4.2e-05	CcSEcCtD
Paliperidone—Headache—Prednisone—hematologic cancer	1.59e-05	4.18e-05	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Doxorubicin—hematologic cancer	1.58e-05	4.17e-05	CcSEcCtD
Paliperidone—Fatigue—Doxorubicin—hematologic cancer	1.58e-05	4.17e-05	CcSEcCtD
Paliperidone—Urticaria—Epirubicin—hematologic cancer	1.57e-05	4.15e-05	CcSEcCtD
Paliperidone—Constipation—Doxorubicin—hematologic cancer	1.57e-05	4.13e-05	CcSEcCtD
Paliperidone—Pain—Doxorubicin—hematologic cancer	1.57e-05	4.13e-05	CcSEcCtD
Paliperidone—Abdominal pain—Epirubicin—hematologic cancer	1.57e-05	4.13e-05	CcSEcCtD
Paliperidone—Body temperature increased—Epirubicin—hematologic cancer	1.57e-05	4.13e-05	CcSEcCtD
Paliperidone—Hypersensitivity—Methotrexate—hematologic cancer	1.56e-05	4.11e-05	CcSEcCtD
Paliperidone—Asthenia—Methotrexate—hematologic cancer	1.52e-05	4e-05	CcSEcCtD
Paliperidone—Feeling abnormal—Doxorubicin—hematologic cancer	1.51e-05	3.98e-05	CcSEcCtD
Paliperidone—Nausea—Prednisone—hematologic cancer	1.5e-05	3.97e-05	CcSEcCtD
Paliperidone—Gastrointestinal pain—Doxorubicin—hematologic cancer	1.5e-05	3.95e-05	CcSEcCtD
Paliperidone—Pruritus—Methotrexate—hematologic cancer	1.5e-05	3.95e-05	CcSEcCtD
Paliperidone—Hypersensitivity—Epirubicin—hematologic cancer	1.46e-05	3.85e-05	CcSEcCtD
Paliperidone—Urticaria—Doxorubicin—hematologic cancer	1.46e-05	3.84e-05	CcSEcCtD
Paliperidone—Body temperature increased—Doxorubicin—hematologic cancer	1.45e-05	3.82e-05	CcSEcCtD
Paliperidone—Abdominal pain—Doxorubicin—hematologic cancer	1.45e-05	3.82e-05	CcSEcCtD
Paliperidone—Diarrhoea—Methotrexate—hematologic cancer	1.45e-05	3.82e-05	CcSEcCtD
Paliperidone—Asthenia—Epirubicin—hematologic cancer	1.42e-05	3.75e-05	CcSEcCtD
Paliperidone—Pruritus—Epirubicin—hematologic cancer	1.4e-05	3.69e-05	CcSEcCtD
Paliperidone—Dizziness—Methotrexate—hematologic cancer	1.4e-05	3.69e-05	CcSEcCtD
Paliperidone—Diarrhoea—Epirubicin—hematologic cancer	1.36e-05	3.57e-05	CcSEcCtD
Paliperidone—Hypersensitivity—Doxorubicin—hematologic cancer	1.35e-05	3.56e-05	CcSEcCtD
Paliperidone—Vomiting—Methotrexate—hematologic cancer	1.35e-05	3.55e-05	CcSEcCtD
Paliperidone—Rash—Methotrexate—hematologic cancer	1.33e-05	3.52e-05	CcSEcCtD
Paliperidone—Dermatitis—Methotrexate—hematologic cancer	1.33e-05	3.52e-05	CcSEcCtD
Paliperidone—Headache—Methotrexate—hematologic cancer	1.33e-05	3.5e-05	CcSEcCtD
Paliperidone—Asthenia—Doxorubicin—hematologic cancer	1.32e-05	3.47e-05	CcSEcCtD
Paliperidone—Dizziness—Epirubicin—hematologic cancer	1.31e-05	3.45e-05	CcSEcCtD
Paliperidone—Pruritus—Doxorubicin—hematologic cancer	1.3e-05	3.42e-05	CcSEcCtD
Paliperidone—Vomiting—Epirubicin—hematologic cancer	1.26e-05	3.32e-05	CcSEcCtD
Paliperidone—Nausea—Methotrexate—hematologic cancer	1.26e-05	3.31e-05	CcSEcCtD
Paliperidone—Diarrhoea—Doxorubicin—hematologic cancer	1.25e-05	3.31e-05	CcSEcCtD
Paliperidone—Rash—Epirubicin—hematologic cancer	1.25e-05	3.29e-05	CcSEcCtD
Paliperidone—Dermatitis—Epirubicin—hematologic cancer	1.25e-05	3.29e-05	CcSEcCtD
Paliperidone—Headache—Epirubicin—hematologic cancer	1.24e-05	3.27e-05	CcSEcCtD
Paliperidone—Dizziness—Doxorubicin—hematologic cancer	1.21e-05	3.2e-05	CcSEcCtD
Paliperidone—Nausea—Epirubicin—hematologic cancer	1.18e-05	3.1e-05	CcSEcCtD
Paliperidone—Vomiting—Doxorubicin—hematologic cancer	1.17e-05	3.07e-05	CcSEcCtD
Paliperidone—Rash—Doxorubicin—hematologic cancer	1.16e-05	3.05e-05	CcSEcCtD
Paliperidone—Dermatitis—Doxorubicin—hematologic cancer	1.15e-05	3.04e-05	CcSEcCtD
Paliperidone—Headache—Doxorubicin—hematologic cancer	1.15e-05	3.03e-05	CcSEcCtD
Paliperidone—Nausea—Doxorubicin—hematologic cancer	1.09e-05	2.87e-05	CcSEcCtD
Paliperidone—DRD2—Signaling Pathways—IL2—hematologic cancer	2.81e-06	2.25e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—MAPK8—hematologic cancer	2.8e-06	2.25e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling by GPCR—AKT1—hematologic cancer	2.8e-06	2.24e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling by GPCR—IL6—hematologic cancer	2.79e-06	2.24e-05	CbGpPWpGaD
Paliperidone—HTR2A—GPCR downstream signaling—AKT1—hematologic cancer	2.79e-06	2.24e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—SRC—hematologic cancer	2.79e-06	2.24e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—STAT3—hematologic cancer	2.79e-06	2.24e-05	CbGpPWpGaD
Paliperidone—HRH1—GPCR downstream signaling—AKT1—hematologic cancer	2.79e-06	2.24e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—PIK3CA—hematologic cancer	2.79e-06	2.24e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PIK3CG—hematologic cancer	2.78e-06	2.23e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—NRAS—hematologic cancer	2.78e-06	2.23e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—EP300—hematologic cancer	2.78e-06	2.23e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—SRC—hematologic cancer	2.78e-06	2.23e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—CASP3—hematologic cancer	2.77e-06	2.22e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—CDKN1B—hematologic cancer	2.76e-06	2.22e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—IL2—hematologic cancer	2.76e-06	2.22e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—CASP3—hematologic cancer	2.76e-06	2.22e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—IL2—hematologic cancer	2.76e-06	2.21e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—TP53—hematologic cancer	2.75e-06	2.21e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—IL6—hematologic cancer	2.75e-06	2.21e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—IL6—hematologic cancer	2.74e-06	2.2e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—PIK3CA—hematologic cancer	2.74e-06	2.2e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—CCND1—hematologic cancer	2.74e-06	2.2e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—PIK3CB—hematologic cancer	2.74e-06	2.2e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—MTOR—hematologic cancer	2.74e-06	2.2e-05	CbGpPWpGaD
Paliperidone—ADRA1A—GPCR downstream signaling—AKT1—hematologic cancer	2.73e-06	2.2e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—EP300—hematologic cancer	2.73e-06	2.19e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—JUN—hematologic cancer	2.73e-06	2.19e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—VEGFA—hematologic cancer	2.72e-06	2.18e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—CASP3—hematologic cancer	2.71e-06	2.18e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—IL2—hematologic cancer	2.71e-06	2.17e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—VEGFA—hematologic cancer	2.7e-06	2.17e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—SRC—hematologic cancer	2.7e-06	2.17e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—EP300—hematologic cancer	2.7e-06	2.17e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—TP53—hematologic cancer	2.7e-06	2.16e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—CCND1—hematologic cancer	2.69e-06	2.16e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—IL6—hematologic cancer	2.69e-06	2.16e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—STAT3—hematologic cancer	2.69e-06	2.16e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—JUN—hematologic cancer	2.69e-06	2.16e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—CCND1—hematologic cancer	2.69e-06	2.16e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—KRAS—hematologic cancer	2.69e-06	2.16e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—NRAS—hematologic cancer	2.68e-06	2.16e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—JUN—hematologic cancer	2.68e-06	2.15e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—STAT3—hematologic cancer	2.68e-06	2.15e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—NRAS—hematologic cancer	2.67e-06	2.14e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—GSTP1—hematologic cancer	2.67e-06	2.14e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—MAPK3—hematologic cancer	2.66e-06	2.14e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—SRC—hematologic cancer	2.66e-06	2.13e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—TP53—hematologic cancer	2.65e-06	2.13e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—KRAS—hematologic cancer	2.65e-06	2.13e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—CDKN1A—hematologic cancer	2.65e-06	2.13e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—PTEN—hematologic cancer	2.64e-06	2.12e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—CCND1—hematologic cancer	2.64e-06	2.12e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—HRAS—hematologic cancer	2.63e-06	2.11e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—JUN—hematologic cancer	2.63e-06	2.11e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—VEGFA—hematologic cancer	2.63e-06	2.11e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—HRAS—hematologic cancer	2.61e-06	2.1e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—CDKN1A—hematologic cancer	2.61e-06	2.09e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—STAT3—hematologic cancer	2.6e-06	2.09e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—CDKN1A—hematologic cancer	2.6e-06	2.09e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—PTEN—hematologic cancer	2.6e-06	2.09e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—NRAS—hematologic cancer	2.6e-06	2.09e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—PTEN—hematologic cancer	2.59e-06	2.08e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—PTEN—hematologic cancer	2.59e-06	2.08e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—MYC—hematologic cancer	2.59e-06	2.08e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—VEGFA—hematologic cancer	2.59e-06	2.08e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—MAPK8—hematologic cancer	2.58e-06	2.07e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—TGFB1—hematologic cancer	2.58e-06	2.07e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—CREBBP—hematologic cancer	2.58e-06	2.07e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—HRAS—hematologic cancer	2.58e-06	2.07e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling by GPCR—AKT1—hematologic cancer	2.58e-06	2.07e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—MAPK3—hematologic cancer	2.57e-06	2.06e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—CDKN1B—hematologic cancer	2.57e-06	2.06e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—STAT3—hematologic cancer	2.56e-06	2.06e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—MAPK3—hematologic cancer	2.56e-06	2.05e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—NRAS—hematologic cancer	2.56e-06	2.05e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—CDKN1A—hematologic cancer	2.55e-06	2.05e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—PTEN—hematologic cancer	2.55e-06	2.04e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—MAPK8—hematologic cancer	2.54e-06	2.04e-05	CbGpPWpGaD
Paliperidone—ADRA2A—GPCR downstream signaling—AKT1—hematologic cancer	2.54e-06	2.04e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—MAPK8—hematologic cancer	2.54e-06	2.04e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—HRAS—hematologic cancer	2.54e-06	2.04e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—AKT1—hematologic cancer	2.54e-06	2.04e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—AKT1—hematologic cancer	2.53e-06	2.03e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—ABCB1—hematologic cancer	2.52e-06	2.03e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—IL6—hematologic cancer	2.52e-06	2.02e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—EP300—hematologic cancer	2.52e-06	2.02e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—CASP3—hematologic cancer	2.52e-06	2.02e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—IL2—hematologic cancer	2.51e-06	2.02e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—IL6—hematologic cancer	2.5e-06	2.01e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—MYC—hematologic cancer	2.5e-06	2.01e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—TGFB1—hematologic cancer	2.49e-06	2e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—MAPK8—hematologic cancer	2.49e-06	2e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—MAPK3—hematologic cancer	2.49e-06	2e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—MYC—hematologic cancer	2.49e-06	2e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—AKT1—hematologic cancer	2.48e-06	1.99e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—TGFB1—hematologic cancer	2.48e-06	1.99e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—EP300—hematologic cancer	2.48e-06	1.99e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—EP300—hematologic cancer	2.47e-06	1.99e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—EP300—hematologic cancer	2.47e-06	1.98e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—PIK3CA—hematologic cancer	2.47e-06	1.98e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—IL6—hematologic cancer	2.47e-06	1.98e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Metabolism—PIK3CA—hematologic cancer	2.46e-06	1.97e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—NCOR1—hematologic cancer	2.45e-06	1.97e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—GSTM1—hematologic cancer	2.45e-06	1.97e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—CCND1—hematologic cancer	2.45e-06	1.97e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—SRC—hematologic cancer	2.45e-06	1.97e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—MAPK3—hematologic cancer	2.45e-06	1.97e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PIK3CD—hematologic cancer	2.45e-06	1.96e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—JUN—hematologic cancer	2.45e-06	1.96e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—PIK3CA—hematologic cancer	2.44e-06	1.96e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—IL6—hematologic cancer	2.43e-06	1.95e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—EP300—hematologic cancer	2.43e-06	1.95e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—MYC—hematologic cancer	2.42e-06	1.94e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—ALB—hematologic cancer	2.42e-06	1.94e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—TGFB1—hematologic cancer	2.41e-06	1.94e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—SRC—hematologic cancer	2.41e-06	1.94e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—SRC—hematologic cancer	2.41e-06	1.93e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—KRAS—hematologic cancer	2.39e-06	1.92e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—TP53—hematologic cancer	2.39e-06	1.92e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—VEGFA—hematologic cancer	2.39e-06	1.92e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—MYC—hematologic cancer	2.38e-06	1.91e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—TGFB1—hematologic cancer	2.38e-06	1.91e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—CDKN1A—hematologic cancer	2.37e-06	1.9e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—PTEN—hematologic cancer	2.37e-06	1.9e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—STAT3—hematologic cancer	2.36e-06	1.9e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—SRC—hematologic cancer	2.36e-06	1.9e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—NRAS—hematologic cancer	2.36e-06	1.89e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—TP53—hematologic cancer	2.36e-06	1.89e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—VEGFA—hematologic cancer	2.35e-06	1.88e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—VEGFA—hematologic cancer	2.34e-06	1.88e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—STAT3—hematologic cancer	2.32e-06	1.87e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—AKT1—hematologic cancer	2.32e-06	1.87e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—STAT3—hematologic cancer	2.32e-06	1.86e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—NRAS—hematologic cancer	2.32e-06	1.86e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—NRAS—hematologic cancer	2.31e-06	1.86e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—MAPK8—hematologic cancer	2.31e-06	1.86e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PIK3R1—hematologic cancer	2.31e-06	1.85e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—KRAS—hematologic cancer	2.31e-06	1.85e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—AKT1—hematologic cancer	2.31e-06	1.85e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—VEGFA—hematologic cancer	2.3e-06	1.85e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—KRAS—hematologic cancer	2.3e-06	1.85e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—HRAS—hematologic cancer	2.28e-06	1.83e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—AKT1—hematologic cancer	2.28e-06	1.83e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—STAT3—hematologic cancer	2.28e-06	1.83e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—NRAS—hematologic cancer	2.27e-06	1.82e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—MAPK3—hematologic cancer	2.26e-06	1.81e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—EP300—hematologic cancer	2.26e-06	1.81e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—HRAS—hematologic cancer	2.25e-06	1.81e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—AKT1—hematologic cancer	2.24e-06	1.8e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—KRAS—hematologic cancer	2.24e-06	1.79e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—MAPK3—hematologic cancer	2.22e-06	1.78e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—MAPK3—hematologic cancer	2.22e-06	1.78e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—KRAS—hematologic cancer	2.2e-06	1.77e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—PIK3CA—hematologic cancer	2.2e-06	1.77e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—MYC—hematologic cancer	2.2e-06	1.76e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—SRC—hematologic cancer	2.19e-06	1.76e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—TGFB1—hematologic cancer	2.19e-06	1.76e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—IL6—hematologic cancer	2.19e-06	1.75e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—MAPK3—hematologic cancer	2.17e-06	1.75e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—MTHFR—hematologic cancer	2.17e-06	1.74e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—MYC—hematologic cancer	2.16e-06	1.73e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—IL6—hematologic cancer	2.16e-06	1.73e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—MYC—hematologic cancer	2.16e-06	1.73e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—TGFB1—hematologic cancer	2.16e-06	1.73e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—TGFB1—hematologic cancer	2.15e-06	1.73e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—VEGFA—hematologic cancer	2.14e-06	1.71e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PIK3CB—hematologic cancer	2.13e-06	1.71e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—TP53—hematologic cancer	2.13e-06	1.71e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—PIK3CA—hematologic cancer	2.12e-06	1.7e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—MYC—hematologic cancer	2.12e-06	1.7e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—STAT3—hematologic cancer	2.12e-06	1.7e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—PIK3CA—hematologic cancer	2.11e-06	1.7e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—TGFB1—hematologic cancer	2.11e-06	1.69e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—NRAS—hematologic cancer	2.11e-06	1.69e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—PIK3CA—hematologic cancer	2.05e-06	1.65e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—TP53—hematologic cancer	2.05e-06	1.65e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—TP53—hematologic cancer	2.04e-06	1.64e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—HRAS—hematologic cancer	2.03e-06	1.63e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—KRAS—hematologic cancer	2.03e-06	1.63e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—PIK3CA—hematologic cancer	2.02e-06	1.62e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—MAPK3—hematologic cancer	2.02e-06	1.62e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—AKT1—hematologic cancer	2.02e-06	1.62e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Metabolism—AKT1—hematologic cancer	2.01e-06	1.61e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—KRAS—hematologic cancer	2e-06	1.6e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—PIK3CA—hematologic cancer	2e-06	1.6e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—KRAS—hematologic cancer	1.99e-06	1.6e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—AKT1—hematologic cancer	1.99e-06	1.6e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—TP53—hematologic cancer	1.99e-06	1.6e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—MYC—hematologic cancer	1.97e-06	1.58e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—HRAS—hematologic cancer	1.96e-06	1.58e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—TGFB1—hematologic cancer	1.96e-06	1.57e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—TP53—hematologic cancer	1.96e-06	1.57e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—KRAS—hematologic cancer	1.95e-06	1.57e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—HRAS—hematologic cancer	1.95e-06	1.57e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—IL6—hematologic cancer	1.95e-06	1.56e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—HRAS—hematologic cancer	1.9e-06	1.53e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—IL6—hematologic cancer	1.88e-06	1.51e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—HRAS—hematologic cancer	1.87e-06	1.5e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—IL6—hematologic cancer	1.87e-06	1.5e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—PIK3CA—hematologic cancer	1.86e-06	1.5e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PTEN—hematologic cancer	1.84e-06	1.48e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—PIK3CA—hematologic cancer	1.83e-06	1.47e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—PIK3CA—hematologic cancer	1.83e-06	1.47e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—PIK3CA—hematologic cancer	1.83e-06	1.47e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PIK3CG—hematologic cancer	1.82e-06	1.46e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—IL6—hematologic cancer	1.82e-06	1.46e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—KRAS—hematologic cancer	1.82e-06	1.46e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—TP53—hematologic cancer	1.8e-06	1.45e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—AKT1—hematologic cancer	1.8e-06	1.44e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—PIK3CA—hematologic cancer	1.8e-06	1.44e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—IL6—hematologic cancer	1.79e-06	1.44e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—TP53—hematologic cancer	1.77e-06	1.42e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—TP53—hematologic cancer	1.77e-06	1.42e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—EP300—hematologic cancer	1.76e-06	1.41e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—TP53—hematologic cancer	1.74e-06	1.39e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—AKT1—hematologic cancer	1.73e-06	1.39e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—AKT1—hematologic cancer	1.73e-06	1.39e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—HRAS—hematologic cancer	1.72e-06	1.38e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—HRAS—hematologic cancer	1.7e-06	1.36e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—HRAS—hematologic cancer	1.69e-06	1.36e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—CREBBP—hematologic cancer	1.69e-06	1.35e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—AKT1—hematologic cancer	1.68e-06	1.35e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—PIK3CA—hematologic cancer	1.67e-06	1.34e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—HRAS—hematologic cancer	1.66e-06	1.33e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—AKT1—hematologic cancer	1.65e-06	1.33e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—IL6—hematologic cancer	1.65e-06	1.32e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—AKT1—hematologic cancer	1.63e-06	1.31e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—IL6—hematologic cancer	1.62e-06	1.3e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—IL6—hematologic cancer	1.62e-06	1.3e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—TP53—hematologic cancer	1.61e-06	1.3e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PIK3CD—hematologic cancer	1.6e-06	1.28e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—IL6—hematologic cancer	1.59e-06	1.28e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—ALB—hematologic cancer	1.58e-06	1.27e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—HRAS—hematologic cancer	1.54e-06	1.24e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—AKT1—hematologic cancer	1.52e-06	1.22e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PIK3R1—hematologic cancer	1.51e-06	1.21e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—AKT1—hematologic cancer	1.5e-06	1.2e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—AKT1—hematologic cancer	1.49e-06	1.2e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—AKT1—hematologic cancer	1.49e-06	1.2e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—IL6—hematologic cancer	1.48e-06	1.19e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—AKT1—hematologic cancer	1.47e-06	1.18e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PIK3CB—hematologic cancer	1.39e-06	1.12e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—AKT1—hematologic cancer	1.36e-06	1.09e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PIK3CA—hematologic cancer	1.3e-06	1.04e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PTEN—hematologic cancer	1.21e-06	9.67e-06	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—EP300—hematologic cancer	1.15e-06	9.23e-06	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—AKT1—hematologic cancer	1.06e-06	8.53e-06	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PIK3CA—hematologic cancer	8.5e-07	6.82e-06	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—AKT1—hematologic cancer	6.94e-07	5.57e-06	CbGpPWpGaD
